



Figure S1 The evolution of the chosen treatment for patients with KRAS G12C mutations in NSCLC. FDA, Food and Drug Administration; NMPA, the National Medical Products Administration; NSCLC, non-small cell lung cancer; RTKs, receptor tyrosine kinase; SHP2, Src homology phosphatase 2; SND, Sini decoction; SOS1, son of sevenless 1; SM-WD, Shengmai-water decoction.